Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)

CompletedOBSERVATIONAL
Enrollment

97

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Human Immunodeficiency Virus Infection
Trial Locations (20)

8036

Site Ref # / Investigator 52270, Barcelona

11407

Site Ref # / Investigator 52263, Jerez de La Frontera (Cadiz)

12004

Site Ref # / Investigator 53650, Castellon

15006

Site Ref # / Investigator 52274, A Coruña

15405

Site Ref # / Investigator 52273, Ferrol (A Coruna)

18014

Site Ref # / Investigator 52264, Granada

23007

Site Ref # / Investigator 52262, Jaén

28007

Site Ref # / Investigator 52345, Madrid

28034

Site Ref # / Investigator 52275, Madrid

28046

Site Ref # / Investigator 52302, Madrid

28880

Site Ref # / Investigator 52343, Madrid

28905

Site Ref # / Investigator 52344, Madrid

30003

Site Ref # / Investigator 53648, Murcia

30203

Site Ref # / Investigator 52362, Cartagena

43201

Site Ref # / Investigator 52268, Reus (Tarragona)

46009

Site Ref # / Investigator 52272, Valencia

48903

Site Ref # / Investigator 52363, Barakaldo

50009

Site Ref # / Investigator 52266, Zaragoza

08035

Site Ref # / Investigator 52271, Barcelona

08906

Site Ref # / Investigator 52267, L'Hospitalet de Llobregat

All Listed Sponsors
collaborator

Triaca Magna, SA

UNKNOWN

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01383005 - Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) | Biotech Hunter | Biotech Hunter